Search Bar & Filters
Found 24 Actively Recruiting clinical trials
Actively Recruiting
Researchers are examining how often acute rehabilitation practices are used for children in pediatric intensive care units PICUs. This observational study focuses on children and adolescents admitted to PICUs across 13 hospitals. The main goal is to understand the prevalence and types of rehabilitation care provided during critical care in children aged 18 years or younger. The study does not assign treatments but observes routine clinical rehabilitation practices that children receive as part of their standard care in the PICU. Data will be collected at three specific times spaced about six months apart over an 18-month period to assess how often rehabilitation occurs, the number of sessions, types of interventions, use of assistive devices, and delivery methods. Participants will be monitored through these three seasonal point-prevalence assessments. Researchers will collect detailed information about the rehabilitation sessions, factors affecting whether rehabilitation is provided, and characteristics of the interventions. The total participation period spans these assessments over 18 months, with careful observation but no additional interventions beyond usual care.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
This research aims to collect and evaluate safety and effectiveness information about Jyseleca tablet Filgotinib Maleate 100 mg and 200 mg in Korean participants using it in real-world conditions. The study focuses on monitoring serious and non-serious adverse events and drug reactions, including unexpected ones, as well as changes in disease activity scores related to rheumatoid arthritis and ulcerative colitis. Participants prescribed Jyseleca according to Korean approved therapeutic indications will be observed without additional intervention. They will be followed for up to 24 weeks or until they stop treatment due to adverse events or other reasons. The study includes adults with rheumatoid arthritis or ulcerative colitis who have not responded well or are intolerant to prior treatments. During the study, researchers will track adverse events and reactions from enrollment through 24 weeks. They will also measure changes in disease activity scores at baseline, week 12, and week 24. Participants will have regular monitoring visits as part of their usual care, with data collected about safety and treatment effects. The total participation time is up to 24 weeks.
Actively Recruiting
This research focuses on patients who have had an Embolic Stroke of Undetermined Source ESUS and have received an Implantable Cardiac Monitor ICM. It evaluates the use of an artificial intelligence tool called SmartECG-AF, which analyzes standard 12-lead ECGs taken during normal heart rhythm to predict the risk of developing atrial fibrillation AF. The study aims to understand if this AI tool can help identify which patients are more likely to experience AF and major cardiovascular events after ESUS. Participants will be divided into two groups based on the AIs risk assessment a High Risk group and a Low to Intermediate Risk group. The study will follow these groups over time to compare the frequency and timing of AF events detected by the ICM. This multicenter, prospective study will also explore the relationship between the AI risk scores and the occurrence of major adverse cardiovascular events, helping to assess the value of AI-guided risk stratification. During the study, patients baseline ECGs will be analyzed by the AI algorithm, and their heart rhythm will be monitored continuously through the ICM. Researchers will track the time to AF events and record any major cardiovascular incidents over a follow-up period of up to 12 months. Participants will be monitored for safety and clinical outcomes, providing data on how well the AI tool predicts cardiac risks in this population.
Actively Recruiting
This research aims to collect long-term safety and disease progression data on patients diagnosed with atypical hemolytic-uremic syndrome aHUS, including those treated or untreated with the drugs eculizumab or ravulizumab. The study is observational and involves multiple centers and countries, focusing on real-world information after these treatments have been marketed. Participants include patients of any age diagnosed with aHUS, regardless of whether they have identified complement genetic variants or antibodies. The study gathers data without administering new treatments, monitoring patients who may or may not have received eculizumab or ravulizumab. The registry collects information over extended periods to understand safety events and disease course. During the study, researchers track safety-related events over 10 years and the timing of these events within 5 years. Data collection involves reviewing patient health status and disease progression without altering their usual care. The study relies on informed consent and may include minors with appropriate assent. Participation duration varies, with continuous observation to gather comprehensive post-marketing safety data.
Actively Recruiting
This clinical trial is a phase 2, open-label, multicenter study focused on infants diagnosed with leukemia. It aims to improve survival rates by tailoring the use of chemotherapy and hematopoietic stem cell transplantation based on genetic features at diagnosis and minimal residual disease MRD levels after treatment. The study also seeks to clarify which patient groups need stem cell transplantation and to understand long-term side effects and outcomes related to treatment in infants. Participants are divided into low, intermediate, and high risk groups based on genetic markers and MRD results. Each group receives a specific treatment plan low risk patients undergo induction chemotherapy followed by several consolidation chemotherapy phases and maintenance therapy intermediate risk patients receive induction and high-risk consolidation chemotherapy followed by maintenance high risk patients receive induction, high-risk consolidation chemotherapy, and then hematopoietic stem cell transplantation. Chemotherapy regimens include various drugs such as prednisolone, dexamethasone, vincristine, daunorubicin, and others, delivered over several weeks, with maintenance chemotherapy lasting about two years. During the study, participants will be closely monitored with assessments of overall survival at three years as the primary outcome, along with secondary measures including event-free survival, transplantation rates, recurrence, and treatment-related death rates up to five years. Side effects and long-term effects will be prospectively collected during and after treatment. The total participation period extends up to five years, allowing for comprehensive follow-up to evaluate treatment impact and safety.
Actively Recruiting
Researchers are investigating treatments for children and young adults with relapsed acute lymphoblastic leukemia ALL, including cases with bone marrow recurrence. This phase 2, open-label, multi-center study evaluates outcomes based on risk groups determined by next-generation sequencing minimal residual disease NGS MRD after induction therapy. The risk groups are standard risk, high risk, and very high risk, with classification depending on specific leukemia types and MRD levels. Participants receive treatment plans tailored to their risk group, including combinations of chemotherapy drugs such as prednisolone, vincristine, L-asparaginase, idarubicin, methotrexate, and cytarabine, as well as blinatumomab therapy and hematopoietic stem cell transplantation when appropriate. Treatment phases include reinduction, consolidation, intensification, possible blinatumomab courses, and maintenance, following specific schedules lasting weeks to months depending on the regimen. Throughout the study, participants undergo regular assessments including blood tests, imaging, and performance status evaluations to monitor safety and treatment efficacy for an average of nine years. Outcomes measured include disease-free survival rates, treatment-related death and toxicity rates, and overall safety. The study requires compliance with protocol procedures and informed consent, with ongoing monitoring and care throughout participation.
Actively Recruiting
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.
Actively Recruiting
Researchers are evaluating whether the risk of major adverse cardiac events over two years differs between two methods of guiding Percutaneous Coronary Intervention PCI in patients with Left Main Coronary Artery LMCA disease. The study compares Fractional Flow Reserve FFR-guided PCI and angiography-guided PCI to understand which approach may better influence treatment decisions and outcomes for this condition. Participants will be randomly assigned to receive either FFR-guided PCI or angiography-guided PCI. Both procedures involve using drug-eluting stents to treat significant LMCA disease and may include patients with other coronary artery diseases. The study will monitor participants for two years after their procedure, capturing various heart-related events and treatment outcomes during this period. During the two-year follow-up, participants will have clinical visits and assessments to track events such as death, heart attacks, hospitalizations, repeat procedures, stroke, bleeding, and stent problems. Researchers will also evaluate hospital stay length, procedure details, heart function, quality of life related to angina and health, and medication use. The study aims to provide comprehensive information on the safety and effectiveness of both PCI guidance strategies over this time frame.
1-10 of 24
1